Crystalline rotigotine base and preparation process therefor

ABSTRACT

An isolated and pure crystalline rotigotine base of polymorph Form I, and processes for producing the crystalline rotigotine base are disclosed. Also disclosed is a transdermal patch for the delivery of rotigotine base using the disclosed isolated and pure form of rotigotine base, which can be used in treatment of Parkinson&#39;s Disease and other disorders ameliorated or treated by rotigotine, including restless leg syndrome.

CROSS-REFERENCE TO RELATED APPLICATIONS

This patent application is a divisional of copending U.S. patentapplication Ser. No. 12/601,749, filed Nov. 24, 2009, which is the U.S.national phase of International Patent Application No.PCT/IL/2008/000721, filed on May 28, 2008, which claims the benefit ofU.S. Provisional Application No. 60/940,910, filed May 30, 2007, thedisclosures of which are incorporated herein by reference in theirentireties and for all purposes.

TECHNICAL FIELD

The present invention relates to organic chemistry and more particularlyto crystalline rotigotine base and processes for preparation andpurification therefor.

BACKGROUND OF THE INVENTION

Rotigotine((S)-(−)-5-hydroxy-2-(N-n-propyl-N-2-thienylethyl)-aminotetralin) isrepresented by the following structural formula:

Rotigotine is a non-ergolinic dopamine-receptor agonist, which is usedfor the treatment of the signs and symptoms of early-stage idiopathicParkinson's disease. The drug is administered via a silicon-basedtransdermal delivery patch.

Rotigotine is sold in Europe by Schwarz Pharma as NEUPRO® and wasrecently approved by the FDA for use in the U.S. NEUPRO® is formulatedas 10 cm², 20 cm², 30 cm², and 40 cm² transdermal patches containing 4.5mg, 9.0 mg, 13.5 mg and 18.0 mg rotigotine per base, respectively,designed to release 2 mg, 4 mg, 6 mg and 8 mg, respectively, ofrotigotine per 24 hours.

The preparation of racemic rotigotine hydrochloride is disclosed in U.S.Pat. No. 4,564,628. The process, which is depicted in Scheme 1,comprises reacting 5-methoxy-2-tetralone (Compound I) withβ-(2-thienyl)ethylamine in presence of p-toluenesulfonic acid and sodiumcyanoborohydride to obtain1,2,3,4-tetrahydro-5-methoxy-N-[2-(thienyl)-ethyl]-2-naphthaleneamine(Compound II), which is reacted with propionyl chloride in presence oftriethylamine to obtainN-(1,2,3,4-tetrahydro-5-methoxy-2-naphthenyl)-N-[2-(2-thienyl)ethyl)]propaneamide(Compound III). This propanamide is reduced with lithium aluminumhydride to obtain1,2,3,4-tetrahydro-5-methoxy-N-propyl-N-[2-(2-thienyl)ethyl]-2-naphthaleneamine(Compound IV), which is subsequently reacted with boron tribromide, thenhydrochloric acid (HCl) to form the racemic rotigotine hydrochloride(Compound V).

Another process for preparing racemic rotigotine hydrochloride, which isdisclosed in U.S. Pat. No. 4,564,628, is shown in Scheme 2 below.5-methoxy-2-tetralon (Compound I) is reacted with 3-propylamine inacetic acid and H₂/PtO₂ to obtain1,2,3,4-tetrahydro-5-methoxy-N-propyl-2-naphthaleneamine (Compound VI).This intermediate then is reacted either with 2-thienylacetic acid inpresence of borane trimethylamine complex in xylene or with2-thienylacetyl chloride and lithium aluminum hydride to obtain1,2,3,4-tetrahydro-5-methoxy-N-propyl-N-[2-(2-thienyl)ethyl]-2-naphthaleneamine(Compound IV). Finally, this intermediate is reacted with borontribromide, then with HCl, to form the racemic rotigotine hydrochloride(Compound V).

U.S. Pat. No. 4,885,308 discloses a process for obtaining the twooptical isomers of rotigotine by resolving the racemic2-(N-n-propylamino)-5-methoxytetralin to its two enantiomers, thenconverting each enantiomer to (+) and (−)-rotigotine, using the processdisclosed in U.S. Pat. No. 4,564,628.

The last step in the synthesis of rotigotine, as recited in severalpatents, such as U.S. Pat. Nos. 4,564,628 and 6,372,920, involves thedirect formation of the hydrochloride salt of rotigotine. For instance,none of the five examples of U.S. Pat. No. 6,372,920 detail how theformation of the rotigotine hydrochloride salt is carried out, it isonly mentioned that “rotigotine base is converted to its hydrochloridesalt form in the usual manner.” Example II of U.S. Pat. No. 4,546,628discloses that the free base of rotigotine is obtained by evaporating asolution of rotigotine to dryness, but the resulting residue wasimmediately converted to the hydrochloride salt (without isolation).This HCl salt was characterized and reported to have a melting point of148-150° C.

Although U.S. Pat. Nos. 4,564,628 and 4,885,308 disclose the formationof the free base of rotigotine, using these disclosed procedures resultsin an oil, not in a more desirable solid form, implying that it isdifficult to obtain a crystalline rotigotine base.

According to US Patent Application No. 2004/0048779, rotigotinehydrochloride is converted into rotigotine free base by treatingrotigotine hydrochloride with sodium metasilicate or sodium trisilicatefor 48 hours, or by treating rotigotine hydrochloride with sodiumhydroxide (NaOH) followed by addition of sodium phosphate buffersolution, as disclosed in Examples 3 and 4, respectively. Thus, thepreparation of rotigotine base is in situ, the product is not isolated,and its physical properties have not been reported to in these patentsor patent publications. On the basis of the above mentioned data, it maybe concluded that the previously reported means of synthesizingrotigotine are insufficient for isolating, purifying, and preparing astable form of the rotigotine base suitable for handling and storing.

Because a transdermal delivery patch contains rotigotine base as opposedto rotigotine hydrochloride, a need exists for a solid rotigotine base,preferably in a crystalline form, that can be used as the activematerial in transdermal delivery patches.

SUMMARY OF THE INVENTION

The present invention is directed to methods of preparing rotigotine,i.e., 5-hydroxy-2-(N-n-propyl-N-2-thienylethyl)-aminotetralin, as itsfree base, typically in a solid, crystalline form. This crystallinerotigotine base can be stored at room temperature, purified, and usedwithout the need to convert the base to the hydrochloride salt.

Thus, one aspect of the invention is to provide crystalline rotigotinebase having a purity of at least about 98.5%, by weight, based upon thetotal weight of the sample. In some embodiments, the purity of therotigotine base is at least about 99.5%, by weight.

In some embodiments, the crystalline form of rotigotine base is Form I,which has a characteristic X-ray powder diffraction pattern comprisingpeaks at 14.6, 15.2, 15.6, 16.6, 17.0, 19.7, 20.2, 22.6 and 27.8±0.2degrees 2θ. In various embodiments, the crystalline rotigotine base hasan X-ray powder diffraction pattern as depicted in FIG. 1. In someembodiments, the crystalline rotigotine base has an infrared spectrumhaving absorption bands at 1583, 1466, 1377, 1281, 1203, 1080, 1011,881, 775 and 700±4 cm⁻¹. In specific embodiments, the crystallinerotigotine base has an infrared spectrum as depicted in FIG. 2. In someembodiments, the crystalline rotigotine base has a differential scanningcalorimetry (DSC) curve exhibiting peak onset at about 75° C. Inspecific embodiments, the crystalline rotigotine base has DSC curve asdepicted in FIG. 3. In some embodiments, the crystalline rotigotine basehas melting point of 75-77° C.

Another aspect of the invention is to provide a method of preparingcrystalline rotigotine base comprising:

-   -   (a) dissolving or partially dissolving rotigotine hydrochloride        in a first organic solvent and water;    -   (b) adding a base to form rotigotine base;    -   (c) removing the water and the first organic solvent to form a        residue;    -   (d) adding water and a second organic solvent to the residue;    -   (e) removing the water and the second organic solvent from the        mixture of step (d) to obtain crude rotigotine base; and    -   (f) crystallizing the crude rotigotine base from a third organic        solvent to form crystalline rotigotine base.

In some embodiments, the first organic solvent comprises dichloromethaneor ethyl acetate. In various embodiments, the second organic solventcomprises diethyl ether or t-butyl methyl ether. In some embodiments,the third organic solvent is selected from the group consisting ofn-pentane, n-hexane, cyclohexane, n-heptane, petroleum ether, and amixture thereof.

In various embodiments, the base is selected from the group consistingof sodium carbonate, potassium carbonate, sodium bicarbonate, potassiumbicarbonate, and combinations thereof.

In some embodiments, the method further comprises collecting, washing,and drying the crystalline rotigotine base. In specific embodiments, thecollecting comprises filtering. In some specific embodiments, thewashing comprises washing with a fourth organic solvent selected fromthe group consisting of n-pentane, n-hexane, cyclohexane, n-heptane,petroleum ether, and mixtures thereof.

Another aspect of the invention provides a method of purifying impurerotigotine base comprising:

-   -   (a) admixing the impure rotigotine base with an organic solvent;    -   (b) precipitating purified crystalline rotigotine base from the        mixture of (a); and    -   (c) isolating, washing, optionally milling and drying the        purified crystalline rotigotine base.

In some embodiments the organic solvent of step (a) is selected from thegroup consisting of n-pentane, n-hexane, cyclohexane, n-heptane,petroleum ether, and mixtures thereof. In a specific embodiment, theorganic solvent is n-hexane.

Yet another aspect of the invention provides a method for themanufacture of transdermal patches using rotigotine base Form I.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the X-ray powder diffraction pattern of rotigotine basecrystalline Form I.

FIG. 2 shows the infrared spectrum of rotigotine base crystalline FormI.

FIG. 3 shows the differential scanning calorimetry (DSC) curve ofrotigotine base crystalline Form I.

FIG. 4 shows the thermogravimetric analysis (TGA) curve of rotigotinebase crystalline Form I.

DETAILED DESCRIPTION OF THE INVENTION

Disclosed herein is crystalline rotigotine base, which is alternativelyand interchangeably called throughout this disclosure solid rotigotinebase or polymorph Form I of rotigotine base, and methods of preparingcrystalline rotigotine base and purifying crystalline rotigotine base.The disclosed rotigotine base can be stored room temperature withoutneed to convert it to a salt form.

The precipitation of crystalline rotigotine base can be cumbersome, andis not a simple matter, because an oil can be obtained without usingproper crystallizing conditions, such as solvent and concentrationconditions (see examples 3, 4 and 5). Rotigotine base crystalline Form Iproduces a unique X-ray powder diffraction pattern, as depicted inFIG. 1. The strong diffraction peaks at 14.6, 15.2, 15.6, 16.6, 17.0,19.7, 20.2, 22.6 and 27.8±0.2 degrees 2θ are most characteristic of thisform. The X-ray powder diffraction peak positions and intensitiesexhibited by rotigotine base crystalline Form I are listed in Table 1.

TABLE 1 Peak position Relative 2θ degrees intensity I/I₀ 10.7 7.4 11.21.1 12.6 8.6 13.1 6.2 14.6 52.8 15.2 43.5 15.6 49.5 16.6 36.0 17.0 13.118.2 1.9 19.7 27.6 20.2 100.0 21.7 5.0 21.9 5.2 22.6 25.9 24.3 10.9 24.56.8 25.1 15.4 25.4 9.3 26.2 10.4 27.3 5.6 27.8 21.4 28.6 1.6 29.5 9.931.0 1.4 31.5 6.5 31.9 4.1 33.7 5.6 34.7 2.4

Crystalline rotigotine base Form I further produces a unique infraredspectrum as depicted in FIG. 2. The characteristic infrared spectrumabsorption bands of the crystalline rotigotine base Form I are at 1583,1466, 1377, 1281, 1203, 1080, 1011, 881, 775 and 700±4 cm⁻¹.

Further, rotigotine base crystalline Form I produces a characteristicDSC curve, exhibiting peak onset at about 75±1° C., as depicted in FIG.3. The melting point of the rotigotine base Form I of the presentinvention is 75-77° C.

Rotigotine base crystalline form I produces a TGA curve as depicted inFIG. 4. It may be understood from analyzing the TGA curve of thecrystalline rotigotine base Form I, that the compound (a) does notdecompose on heating, (b) does not lose any volatile molecule (e.g., asolvent molecule), namely the crystalline rotigotine base form I is nota solvate or a hydrate, and (c) is thermally stable.

The present invention discloses a method of preparing crystallinerotigotine base comprising:

-   -   (a) dissolving or partially dissolving rotigotine hydrochloride        in a first organic solvent and water;    -   (b) adding a base to form rotigotine base;    -   (c) removing the water and the first organic solvent to form a        residue;    -   (d) adding water and a second organic solvent to the residue;    -   (e) removing the water and the second organic solvent from the        mixture of step (d) to obtain rotigotine base; and    -   (f) crystallizing the rotigotine base obtained in step (e) from        a third organic solvent to form crystalline rotigotine base. In        some embodiments, the method further comprises collecting,        washing, and drying the crystalline rotigotine base.

The term “dissolving” or “partially dissolving” as used herein refers topreparing a solution of the rotigotine base or hydrochloride salt in anorganic solvent. In cases where the rotigotine does not fully dissolvein the organic solvent, the resulting mixture is a partial solution.

The first organic solvent is typically dichloromethane, but can be alsoethyl acetate. The second organic solvent is typically diethyl ether,but can be also t-butyl methyl ether. The third organic solvent istypically n-pentane, n-hexane, cyclohexane, n-heptane, petroleum ether,or a mixture thereof.

The concentration of the solution or partial solution of impurerotigotine base is typically up to about 0.5 mg/mL. The concentrationcan be about 0.09 mg/mL to about 0.1 mg/mL. In some cases, theconcentration can be about 0.01 mg/mL to about 0.4 mg/mL, about 0.05mg/mL to about 0.3 mg/mL, about 0.07 mg/mL to about 0.2 mg/mL, or about0.08 mg/mL to about 0.15 mg/mL.

The solution or partial solution optionally can be cooled prior to orduring crystallization. Typically the solution or partial solution iscrystallized at ambient (about 22 to about 25° C.) temperatures. Othertemperatures include about 10° C. to about 25° C. and about 15° C. toabout 25° C.

The base that is added to the solution or partial solution can be anyinorganic or organic base compatible with rotigotine. By “compatible” ismeant that the base does not chemically alter the structure ofrotigotine via isomerization, epimerization, dehydration, or the like.Specific bases that can be used include, but are not limited to, sodiumbicarbonate, sodium carbonate, potassium carbonate, potassiumbicarbonate, and combinations thereof. Preferably, the base is sodiumbicarbonate or sodium carbonate.

Rotigotine base or rotigotine free base refers to a form of rotigotinewhich does not have an associate acid addition salt, e.g.,hydrochloride, hydrobromide, citrate, sulfate, phosphate, or the like.

The removal of water and the first organic solvent to form the residuecan be via a number of means, including separating the aqueous andorganic phases, then evaporating the organic phase to form the residue.Alternatively, the water and organic solvent can simultaneously beremoved via evaporation, optionally under reduced pressure. In apreferred embodiment, the water and organic phases are separated and theorganic solvent of the organic phase is removed or partially removed viaevaporation.

The crystals of rotigotine base can be collected using a number oftechniques, but preferably are collected via filtration. The crystalsthen can be washed with a suitable organic solvent, such as n-pentane,n-hexane, cyclohexane, n-heptane or petroleum ether.

Another aspect of the invention provides a method of purifying impurerotigotine base comprising:

-   -   (a) admixing the impure rotigotine base with an organic solvent;    -   (b) precipitating purified crystalline rotigotine base from the        mixture of (a); and    -   (c) isolating, washing, optionally milling and drying the        crystalline rotigotine base.

The term “impure,” as used herein, refers to a compound, typicallyrotigotine base, having up to 93% by weight of that compound in thesample.

The term “pure,” as used herein, refers to a compound, typicallyrotigotine base, having greater than 94% by weight of that compound inthe sample. In some embodiments, rotigotine base has a purity of atleast 98.5%, at least 99.5%, or at least 99.8% by weight. The purity ofa sample can be determined using techniques known in the art, includingliquid and gas chromatography.

Typically, the organic solvent used for precipitating the impurerotigotine base is selected from the group consisting of n-pentane,n-hexane, cyclohexane, n-heptane, petroleum ether, and mixtures thereof.A preferred organic solvent is n-hexane.

Another aspect of the invention provides a method of manufacturing atransdermal patch of rotigotine base comprising using crystallinerotigotine base as disclosed herein to prepare a transdermal patch. Ingeneral, means of making rotigotine transdermal patches are disclosed inU.S. Pat. No. 6,929,801, which is incorporated by reference in itsentirety herein. In some cases, the crystalline rotigotine base ispolymorph Form I.

The use of the terms “a” and “an” and “the” and similar referents in thecontext of describing the invention (especially in the context of thefollowing claims) are to be construed to cover both the singular and theplural, unless otherwise indicated herein or clearly contradicted bycontext. The terms “comprising,” “having,” “including,” and “containing”are to be construed as open-ended terms (i.e., meaning “including, butnot limited to,”) unless otherwise noted. Recitation of ranges of valuesherein are merely intended to serve as a shorthand method of referringindividually to each separate value falling within the range, unlessotherwise indicated herein, and each separate value is incorporated intothe specification as if it were individually recited herein.

All methods described herein can be performed in any suitable orderunless otherwise indicated herein or otherwise clearly contradicted bycontext. The use of any and all examples, or exemplary language (e.g.,“such as”) provided herein, is intended merely to better illustrate theinvention and does not pose a limitation on the scope of the inventionunless otherwise claimed. No language in the specification should beconstrued as indicating any non-claimed element as essential to thepractice of the invention.

Preferred embodiments of this invention are described herein. Variationsof those preferred embodiments may become apparent to those of ordinaryskill in the art upon reading the foregoing description. The inventorsexpect skilled artisans to employ such variations as appropriate, andthe inventors intend for the invention to be practiced otherwise than asspecifically described herein. Accordingly, this invention includes allmodifications and equivalents of the subject matter recited in theclaims appended hereto as permitted by applicable law. Moreover, anycombination of the above-described elements in all possible variationsthereof is encompassed by the invention unless otherwise indicatedherein or otherwise clearly contradicted by context.

All references, including publications, patent applications, andpatents, cited herein are hereby incorporated by reference to the sameextent as if each reference were individually and specifically indicatedto be incorporated by reference and were set forth in its entiretyherein.

EXAMPLES

Although, the following examples illustrate the practice of the presentinvention in some of its embodiments, the examples should not beconstrued as limiting the scope of the invention. Other embodiments willbe apparent to one skilled in the art from consideration of thespecification and examples. It is intended that the specification,including the examples, is considered exemplary only without limitingthe scope and spirit of the invention.

General Description of the Equipment

X-ray diffraction data were acquired using a PHILIPS X-raydiffractometer model PW1050-70. System description: Kα1=1.54178 Å,voltage 40 kV, current 28 mA, diversion slit=1°, receiving slit=0.2 mm,scattering slit=1° with a Graphite monochromator. Measurements of 2θvalues typically are accurate to within ±0.2 degrees. Experimentparameters: pattern measured between 2θ=3° and 2θ=30° with 0.05°increments; count time was 0.5 second per increment.

Infrared spectra were run on Nicolet Fourier-transform infraredspectrometer model Avatar 360, with Omnic software version 5.2. Allsamples were run as KBr disks. The current infrared measurements areaccurate to within 4 cm⁻¹.

Differential scanning calorimetry (DSC) measurements were run on TAinstruments model Q1000, with Universal software version 3.88. Sampleswere analyzed inside crimped 40 μl Aluminum pans. The heating rate was10° C./min.

Thermogravimetric analysis (TGA) is the measure of the thermally inducedweight loss of a material as a function of the applied temperature. TheTGA measurement was performed using a TA instruments Q500 Thermalanalyzer with Universal Software (version 3.88). Samples were analyzedinside platinum baskets at heating rate of 5° C./minute.

Reference Example 1

This example demonstrates the preparation of rotigotine base fromrotigotine hydrochloride in a similar fashion to example 4 of US PatentApplication No. 2004/0048779.

A mixture of 1.76 g rotigotine hydrochloride (5 mmol) in 20 ml water and20 ml ethyl acetate, having a pH of about 3, was stirred at roomtemperature and titrated with NaOH 0.1N until complete dissolutionoccurred at about pH of 6.5. The phases were separated and the organicphase was dried with magnesium sulfate and the solvent was evaporatedunder reduced pressure to dryness obtain 1.52 g (4.8 mmol) of a viscousoil of rotigotine base in 96% yield.

Example 2

This example demonstrates the preparation of rotigotine base Form I.

A reaction vessel, equipped with a magnetic stirrer, a dropping funnel,and a pH meter was charged with 50 g of rotigotine hydrochloride atambient temperature, and 750 mL of dichloromethane and 250 mL of waterwere added. The resulting mixture was stirred for about 20 minutes andthe pH was adjusted to 6.5 by dropwise addition of about 170 mL of a 5%solution of sodium bicarbonate. The phases were separated, and theorganic phase was washed twice with 250 mL each of water. The aqueousphase was washed with dichloromethane and the organic phases werecombined and evaporated under vacuum to obtain a solid. Water (250 mL)was added to the solid and the volume was concentrated by distillation.Diethyl ether (10 mL) was added to the residue and evaporated to obtaina solid. n-hexane (500 mL) was added to the solid and the mixture wasstirred overnight at room temperature. Crystals were formed andsubsequently filtered, washed with 50 mL of n-hexane, and dried undervacuum to afford 42 g of crystalline rotigotine base Form I in 94%yield, having a purity of 99.9%, by HPLC.

Example 3

This example describes an attempt to prepare crystalline rotigotine basefrom rotigotine hydrochloride.

A reaction vessel, equipped with a magnetic stirrer, a dropping funnel,and a pH meter, was charged with 2 g of rotigotine hydrochloride atambient temperature and 20 mL of dichloromethane and 30 mL of water wereadded. The mixture was stirred for about 20 minutes and the pH wasadjusted to 7.8 by dropwise addition of about 15 mL of a 5% solution ofsodium bicarbonate. The phases were separated and the organic phase waswashed with 15 mL of water. The aqueous phase was washed with 20 mL ofdichloromethane and the organic phases were combined. About 2 mL ofdiethyl ether was added to the organic phase and the mixture was cooledto 4° C. and stirred overnight at that temperature. An oil was formed,which was isolated and dissolved in acetone. Water was added and themixture was lyophilized but failed to yield a crystalline material.

Examples 4-5

These examples demonstrate other attempts to prepare crystallinerotigotine base from rotigotine hydrochloride.

The same procedure, as described in Example 2, was repeated to obtain asolution of rotigotine base in dichloromethane. Then, about 2 mL ofn-hexane (Example 4) or petroleum ether (Example 5) was added to theorganic phase, and the mixture was cooled to 4° C. and stirred overnightat that temperature. An oil was formed, which was isolated and dissolvedin ethanol. Water was added and the mixture was lyophilized but failedto yield a crystalline material.

Example 6

This example demonstrates the preparation of solid rotigotine base fromrotigotine hydrochloride.

A reaction vessel, equipped with a magnetic stirrer, a dropping funnel,and a pH meter, was charged with 5 g of rotigotine hydrochloride (14mmol) at ambient temperature, and 75 mL of dichloromethane was added.The mixture was stirred for about 20 minutes and the pH was adjusted to8 by dropwise addition of about 27 mL of a 5% solution of sodiumcarbonate. The mixture was stirred for 4 hours after which time thephases were separated and the aqueous phase was washed with 25 mL ofdichloromethane. The organic phases were combined, washed with 2×25 mLwater and dried over magnesium sulfate. The solvent was evaporated anddiethyl ether (5 mL) was added to the thus formed residue and evaporatedusing rotary evaporator. Then, n-hexane was added to the thus formedresidue and mixed until a white solid was formed. The solid was obtainedby filtration, milled, washed with n-hexane (10 ml) and dried in vacuumto obtain 4.2 g (95% yield) of solid rotigotine base.

What is claimed is:
 1. Solid rotigotine base.
 2. The solid rotigotinebase of claim 1, which is in crystalline form, having X-ray powderdiffraction pattern comprising peaks at 14.6, 15.2, 15.6, 16.6, 17.0,19.7, 20.2, 22.6 and 27.8 degrees 2θ.
 3. The crystalline rotigotine baseof claim 2 having an infrared spectrum comprising absorption peaks at1583±4, 1466±4, 1377±4, 1281±4, 1203±4, 1080±4, 1011±4, 881±4, 775±4,and 700±4 cm⁻¹.
 4. The crystalline rotigotine base of claim 2 having amelting point of about 75° C. to about 77° C.
 5. The crystallinerotigotine base of claim 2 having a differential scanning calorimetrycurve comprising a peak onset at about 75±1° C.
 6. The crystallinerotigotine base of claim 2 having a purity of at least about 98.5%. 7.The crystalline rotigotine base of claim 6 having a purity of at leastabout 99.5%.